HZNP
Income statement / Annual
Last year (2022), Horizon Therapeutics Public Limited Company's total revenue was $3.63 B,
an increase of 12.48% from the previous year.
In 2022, Horizon Therapeutics Public Limited Company's net income was $521.48 M.
See Horizon Therapeutics Public Limited Company,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
Operating Revenue |
$3.63 B |
$3.23 B |
$2.20 B |
$1.30 B |
$1.21 B |
$1.06 B |
$981.12 M |
$757.04 M |
$296.96 M |
$74.02 M |
Cost of Revenue |
$920.20 M
|
$794.51 M
|
$532.70 M
|
$362.18 M
|
$422.32 M
|
$546.28 M
|
$393.27 M
|
$219.50 M
|
$78.75 M
|
$14.63 M
|
Gross Profit |
$2.71 B
|
$2.43 B
|
$1.67 B
|
$937.85 M
|
$785.25 M
|
$509.96 M
|
$587.85 M
|
$537.54 M
|
$218.20 M
|
$59.39 M
|
Gross Profit Ratio |
0.75
|
0.75
|
0.76
|
0.72
|
0.65
|
0.48
|
0.6
|
0.71
|
0.73
|
0.8
|
Research and Development Expenses |
$437.96 M
|
$431.99 M
|
$209.36 M
|
$103.17 M
|
$82.76 M
|
$224.96 M
|
$60.71 M
|
$41.87 M
|
$17.46 M
|
$10.08 M
|
General & Administrative Expenses |
$1.54 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$287.94 M
|
$219.86 M
|
$88.96 M
|
$23.57 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$320.37 M
|
$220.44 M
|
$120.28 M
|
$68.60 M
|
Selling, General & Administrative Expenses |
$1.54 B
|
$1.45 B
|
$973.23 M
|
$697.11 M
|
$692.49 M
|
$677.36 M
|
$608.31 M
|
$440.31 M
|
$209.23 M
|
$92.16 M
|
Other Expenses |
-$5.57 M
|
$1.79 M
|
$3.39 M
|
-$944,000.00
|
$346,000.00
|
$588,000.00
|
$6.70 M
|
-$10.29 M
|
-$11.25 M
|
$0.00
|
Operating Expenses |
$1.98 B
|
$1.88 B
|
$1.18 B
|
$800.28 M
|
$775.25 M
|
$902.33 M
|
$669.02 M
|
$482.17 M
|
$226.69 M
|
$102.25 M
|
Cost And Expenses |
$2.90 B
|
$2.67 B
|
$1.72 B
|
$1.16 B
|
$1.20 B
|
$1.45 B
|
$1.06 B
|
$701.67 M
|
$305.45 M
|
$116.87 M
|
Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$83.71 M
|
$81.06 M
|
$59.62 M
|
$87.09 M
|
$121.69 M
|
$126.52 M
|
$86.61 M
|
$69.90 M
|
$23.83 M
|
$39.18 M
|
Depreciation & Amortization |
$497.25 M
|
$365.91 M
|
$277.96 M
|
$247.18 M
|
$275.73 M
|
$283.42 M
|
$221.84 M
|
$138.34 M
|
$34.01 M
|
$9.31 M
|
EBITDA |
$1.11 B |
$909.04 M |
$767.98 M |
$373.79 M |
$286.08 M |
-$108.37 M |
$147.37 M |
$55.37 M |
-$8.49 M |
-$42.85 M |
EBITDA Ratio |
0.31
|
0.28
|
0.35
|
0.29
|
0.24
|
-0.1
|
0.15
|
0.24
|
0.05
|
-0.45
|
Operating Income Ratio |
0.17
|
0.17
|
0.22
|
0.1
|
0
|
-0.37
|
-0.15
|
0.07
|
-0.03
|
-0.58
|
Total Other Income/Expenses Net |
-$90.48 M
|
-$80.30 M
|
-$88.38 M
|
-$146.84 M
|
-$121.54 M
|
-$120.91 M
|
-$80.92 M
|
-$188.08 M
|
-$261.20 M
|
-$107.27 M
|
Income Before Tax |
$526.94 M
|
$462.83 M
|
$401.65 M
|
-$20.22 M
|
-$119.15 M
|
-$513.28 M
|
-$228.09 M
|
-$132.71 M
|
-$269.69 M
|
-$150.13 M
|
Income Before Tax Ratio |
0.15
|
0.14
|
0.18
|
-0.02
|
-0.1
|
-0.49
|
-0.23
|
-0.18
|
-0.91
|
-2.03
|
Income Tax Expense |
$5.45 M
|
-$71.66 M
|
$11.85 M
|
-$593.24 M
|
-$44.96 M
|
-$102.75 M
|
-$61.25 M
|
-$172.24 M
|
-$6.08 M
|
-$1.12 M
|
Net Income |
$521.48 M
|
$534.49 M
|
$389.80 M
|
$573.02 M
|
-$74.19 M
|
-$410.53 M
|
-$166.83 M
|
$39.53 M
|
-$263.60 M
|
-$149.01 M
|
Net Income Ratio |
0.14
|
0.17
|
0.18
|
0.44
|
-0.06
|
-0.39
|
-0.17
|
0.05
|
-0.89
|
-2.01
|
EPS |
2.28 |
2.37 |
1.91 |
3.13 |
-0.45 |
-2.52 |
-1.04 |
0.27 |
-3.15 |
-2.34 |
EPS Diluted |
2.22 |
2.27 |
1.81 |
2.9 |
-0.45 |
-2.52 |
-1.04 |
0.25 |
-3.15 |
-2.34 |
Weighted Average Shares Out |
$229.11 M
|
$225.55 M
|
$215.31 M
|
$205.22 M
|
$166.16 M
|
$163.12 M
|
$160.70 M
|
$148.79 M
|
$83.75 M
|
$63.66 M
|
Weighted Average Shares Out Diluted |
$235.24 M
|
$235.68 M
|
$215.31 M
|
$205.22 M
|
$166.16 M
|
$163.12 M
|
$160.70 M
|
$155.92 M
|
$83.75 M
|
$63.66 M
|
Link |
|
|
|
|
|
|
|
|
|
|